Susquehanna Fundamental Investments’s Aprea Therapeutics APRE Stock Holding History

Susquehanna Fundamental Investments’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$91K	Hold	2,455	–	–	﹤0.01%	1459
2021 Q4	$141K	Hold	2,455	–	–	﹤0.01%	1299
2021 Q3	$251K	Buy	+2,455	New	+$223K	﹤0.01%	1461
2020 Q4	–	Sell	-1,225	Closed	-$589K	–	1489
2020 Q3	$589K	Buy	1,225 +585	+91%	+$327K	0.02%	826
2020 Q2	$496K	Buy	+640	New	+$420K	0.02%	619

Other funds holding APRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Susquehanna Fundamental Investments's APRE Position: Q1 2022 in Review

Susquehanna Fundamental Investments held its Aprea Therapeutics (APRE) position steady in Q1 2022 at 2,455 shares worth $91K. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

Susquehanna Fundamental Investments first reported a position in APRE in Q2 2020 and has held it in 5 quarters since. The position peaked at $589K in Q3 2020. 40 funds tracked by Wall St. Rank hold APRE as of Q1 2022.

Susquehanna Fundamental Investments held 2,455 shares of Aprea Therapeutics worth $91K as of Q1 2022.
Susquehanna Fundamental Investments left its Aprea Therapeutics share count unchanged in Q1 2022.
Aprea Therapeutics made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1459 holding.
Susquehanna Fundamental Investments first reported a position in Aprea Therapeutics in Q2 2020 and has held it in 5 quarters since.
Susquehanna Fundamental Investments's Aprea Therapeutics position peaked at $589K in Q3 2020.
40 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.